Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

The ALK tyrosine kinase inhibitor (TKI), crizotinib, shows significant activity in patients whose lung cancers harbor ALK fusions but its efficacy is limited by variable primary responses and acquired resistance. In work arising from the intriguing clinical observation of a patient with ALK fusion+...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Lovly, Christine M., McDonald, Nerina T., Chen, Heidi, Ortiz-Cuaran, Sandra, Heukamp, Lukas C., Yan, Yingjun, Florin, Alexandra, Ozretić, Luka, Lim, Diana, Wang, Lu, Chen, Zhao, Chen, Xi, Lu, Pengcheng, Paik, Paul K., Shen, Ronglai, Jin, Hailing, Buettner, Reinhard, Ansén, Sascha, Perner, Sven, Brockmann, Michael, Bos, Marc, Wolf, Jürgen, Gardizi, Masyar, Wright, Gavin M., Solomon, Benjamin, Russell, Prudence A., Rogers, Toni-Maree, Suehara, Yoshiyuki, Red-Brewer, Monica, Tieu, Rudy, de Stanchina, Elisa, Wang, Qingguo, Zhao, Zhongming, Johnson, David H., Horn, Leora, Wong, Kwok-Kin, Thomas, Roman K., Ladanyi, Marc, Pao, William
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4159407/
https://ncbi.nlm.nih.gov/pubmed/25173427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.3667
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires